Dangers of Rescheduling Marijuana: Expert Witnesses Warn DEA About Psychosis, Pediatric Harm, and Failed Science

Show Notes

In this urgent episode, three nationally recognized physicians — Dr. Philip Drum, Dr. Ken Finn, and Dr. Karen Randall — testify before the DEA to oppose the proposal to move marijuana from Schedule I to Schedule III. Their expert witness statements reveal the medical, scientific, and public‑health dangers that rescheduling would create.

Dr. Philip Drum, a national expert on the Controlled Substances Act, explains why marijuana has never met the FDA’s requirement for “accepted medical use.” He cites more than 9,500 federally funded studies and $4.2 billion in taxpayer‑funded research — none of which resulted in a single FDA‑approved indication. He also exposes the false claim that cannabis “cannot be researched,” showing that marijuana is one of the most heavily studied substances in U.S. history.

Dr. Ken Finn, a pain physician with 30 years of experience, describes how marijuana consistently fails to treat pain, despite widespread belief. He reveals that the DEA’s own internal study — the one being used to justify rescheduling — is secretive, flawed, and cannot be reproduced. He also highlights the extremely low percentage of physicians who recommend cannabis in states where it is legal, comparing the pattern to the opioid pill‑mill era.

Dr. Karen Randall, an emergency physician and pediatric specialist, delivers some of the most alarming warnings. She describes the explosion of pediatric cannabis exposure, the rise of cannabis hyperemesis syndrome, and the growing number of children experiencing cannabis‑induced psychosis — including cases as young as seven years old. She shares a devastating case of a 13‑year‑old girl trading sex for marijuana, illustrating the real‑world consequences of liberalized drug policy and the false messaging that cannabis is “safe” or “healthy.”

Together, these expert witnesses argue that rescheduling marijuana to Schedule III will:

• Mislead the public into believing cannabis is safe
• Increase youth access and exposure
• Expand diversion
• Reduce regulatory oversight
• Ignore decades of medical evidence
• Create long‑term harm to developing brains

This is Part 1 of their testimony before the DEA. Part 2 will be released shortly.

⭐ Expanded Guest Bios

Dr. Philip Drum

Expert Witness – Controlled Substances Act & Drug Scheduling Dr. Philip Drum is a national expert on the Controlled Substances Act, drug scheduling, and FDA medical‑use standards. In his testimony to the DEA, Dr. Drum explained how Schedule I substances are defined, why marijuana has never met the FDA’s requirement for “accepted medical use,” and why the claim that cannabis “cannot be researched” is false. He cited more than 9,500 federally funded studies and $4.2 billion in taxpayer‑funded research on marijuana — none of which resulted in a single FDA‑approved indication. Dr. Drum also detailed the abuse‑potential differences between Schedule I, II, and III substances, and warned that moving marijuana directly to Schedule III ignores decades of scientific evidence.

Dr. Ken Finn

Expert Witness – Pain Medicine & Clinical Evidence Dr. Ken Finn is a pain physician with over 30 years of clinical experience treating patients in Colorado. He has evaluated thousands of patients using opioids and marijuana for pain and testified to the DEA that marijuana consistently fails to treat pain, despite widespread public belief. Dr. Finn highlighted that the DEA’s own internal study supporting rescheduling is secretive, flawed, and cannot be reproduced. He also noted that fewer than 5% of physicians in legal‑cannabis states have ever recommended marijuana, with a small number of doctors issuing the majority of recommendations — a pattern reminiscent of the opioid pill‑mill era.

Dr. Karen Randall

Expert Witness – Emergency Medicine & Pediatric Cannabis Harm Dr. Karen Randall is an emergency physician with specialized expertise in pediatric medicine and adolescent behavioral health. In her testimony to the DEA, she described the dramatic rise in pediatric cannabis exposure, including cases of cannabis‑induced psychosis in children as young as seven years old. She detailed the growing prevalence of cannabis hyperemesis syndrome, a condition causing uncontrollable vomiting that can lead to hospitalization, electrolyte imbalance, and even death. Dr. Randall also shared a devastating case of a 13‑year‑old girl trading sex for marijuana, illustrating the real‑world consequences of liberalized drug messaging and the false belief that cannabis is “safe” or “healthy.” She warned that rescheduling marijuana to Schedule III will increase youth access, worsen diversion, and send a dangerous message to the public.